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empagliflozin does not prolong QT interval in a
thorough QT (TQT) study
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Background: Empagliflozin is a potent, selective sodium glucose cotransporter 2 (SGLT2) inhibitor in development
as an oral antidiabetic treatment. This QT interval study assessed potential effects of empagliflozin on ventricular
repolarisation and other electrocardiogram (ECG) parameters.
Methods: A randomised, placebo-controlled, single-dose, double-blind, five-period crossover study incorporating a
novel double-placebo period design to reduce sample size, while maintaining full statistical power. Treatments:
single empagliflozin doses of 25 mg (therapeutic) and 200 mg (supratherapeutic), matching placebo and open-label
moxifloxacin 400 mg (positive control). Triplicate 12-lead ECGs of 10 second duration were recorded at baseline and
during the first 24 hours after dosing. The primary endpoint was mean change from baseline (MCfB) in the
population heart rate-corrected QT interval (QTcN) between 1–4 hours after dosing.
Results: Thirty volunteers (16 male, 14 female, mean [range] age: 34.5 [18–52] years) were randomised. The
placebo-corrected MCfB in QTcN 1–4 hours after dosing was 0.6 (90% CI: -0.7, 1.9) ms and -0.2 (-1.4, 0.9) ms for
empagliflozin 25 mg and 200 mg, respectively, below the ICH E14 defined threshold of regulatory concern 10 ms.
Assay sensitivity was confirmed by a placebo-corrected MCfB in QTcN 2–4 hours post-dose of 12.4 (10.7, 14.1) ms
with moxifloxacin 400 mg. Empagliflozin tolerability was good for all volunteers; 23.3% experienced adverse events
(AEs) with empagliflozin and 27.6% with placebo. The most frequent AE was nasopharyngitis.
Conclusions/interpretation: Single doses of empagliflozin 25 mg and 200 mg were not associated with QTcN
prolongation and were well tolerated in healthy volunteers.
Trial registration: ClinicalTrials.gov: NCT01195675
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The sodium glucose cotransporter 2 (SGLT2) plays an
important role in glucose homeostasis, being responsible
for around 90% of renal glucose reabsorption [1], and its
inhibition represents a novel approach for the treatment
of type 2 diabetes mellitus (T2DM). SGLT2 inhibitors act
by blocking renal glucose reabsorption via an insulin-* Correspondence: arne.ring@uni-ulm.de
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reproduction in any medium, provided the orindependent mode of action in order to eliminate excess
glucose from the body via the urine [1,2]. Besides their
proven efficacy in lowering plasma glucose levels, these
agents have also been shown to have potential benefits for
improving other cardiovascular risk factors, such as body
weight and blood pressure, while being well tolerated
[3–7].
Empagliflozin is a potent and highly selective SGLT2
inhibitor that has been shown to reduce plasma glucose
levels in patients with T2DM with a low risk of
hypoglycaemia [6,8,9]. Single doses of empagliflozin
(≥800 mg) were rapidly absorbed, reaching peak levels
after 1.5–2.5 hours, with a terminal elimination half-lifed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Comparison of four- and five-period crossover
designs for TQT studies leading to the same statistical
power
Typical four-period New five-period
TQT design TQT design
Placebo periods 1 2
Placebo sessions 40 60
Supratherapeutic dose sessions 40 30
Therapeutic dose sessions 40 30
Active control sessions 40 30
Total number of sessions 160 150
TQT, thorough QT.
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the drug is suitable for once-daily administration. In
addition, no clinically relevant effects of food on drug
exposure were reported [10]. No evidence of cardiac
safety issues have been observed in pre-clinical or Phase
I studies. No relevant interactions with the human
ether-a-go-go related gene (hERG)-mediated potassium
current were measured in transfected human embryonic
kidney cells (HEK293 cells), and empagliflozin doses of
≥10 μM had no effect on action potential configuration
or contractile function of guinea pig papillary muscle
(unpublished data).
QT interval prolongation can be associated with life-
threatening arrhythmias [11,12], and has been docu-
mented with a number of drugs [13]. It is important to
establish the cardiovascular safety of new antidiabetic
drugs as patients with T2DM have a higher risk of
cardiovascular disease (CVD) and CVD-related mortality
[14,15] that can be confounded by hypoglycaemia and
other glucose-independent treatment effects [16,17].
CVD is still the major cause of death in patients with
T2DM [14,18], despite glycaemic control measures
designed to reduce vascular complications related to
glucotoxicity [19,20].
The aim of this study was to confirm the absence of QT
effects with therapeutic and supratherapeutic doses of
empagliflozin compared with moxifloxacin as a positive
control and placebo, using a new five-period crossover
study design, utilising two placebo periods instead of one.
Methods
Study design
This thorough QT study (TQT) was a randomised,
double-blind (moxifloxacin open), placebo-controlled
crossover trial which included the following treatments:
25 mg and 200 mg empagliflozin (Boehringer Ingelheim
Pharma GmbH & Co. KG); 400 mg open-label moxi-
floxacin (Avalox®; Bayer Vital, Leverkusen, Germany); and
two placebo periods, with a washout of at least seven days
between treatments. Trial medication was administered in
the morning after an overnight fast.
Deviating from the conventional four-period design
for TQT studies, this study utilised a five-period design
with two placebo periods [21,22]. Although this design
has not been implemented in a study before, its advan-
tages have been previously recognised by other authors
[21,23]. The design is considered to be advantageous for
TQT trials because all of the required between-treatment
comparisons of ECG intervals are comparisons of active
drug with placebo. Doubling the number of placebo
periods allows the overall sample size to be reduced
[21,23] (Table 1; see sample size section below).
The single oral dose of 25 mg empagliflozin is the
expected daily therapeutic dose, based on an expected meanmaximum plasma concentration (Cmax) of 505 nmol/L
and a mean time to maximum plasma concentration
(tmax) of 2.2 hours in healthy volunteers [10]. The sin-
gle oral dose of 200 mg empagliflozin was chosen as
the supratherapeutic dose, based on an expected mean
Cmax of 3490 nmol/L (~7-fold higher than the thera-
peutic dose) and a mean tmax of 1.8 hours in healthy
volunteers [10].
Moxifloxacin 400 mg was used as a positive control
according to the ICH E14 guidance [24], as this treat-
ment was shown to prolong the heart rate-corrected QT
interval by approximately 6–15 ms compared to placebo
in several clinical trials in healthy volunteers [25–28].
The trial was conducted in accordance with the
Declaration of Helsinki and the International Conference
of Harmonisation Tripartite Guideline for Good Clinical
Practice. The study was approved by the local Ethical
Committee (Landesärztekammer Baden-Württemberg,
Stuttgart, Germany) and the German Competent Authority
(Bundesinstitut für Arzneimittel und Medizinprodukte,
Bonn, Germany). All participants provided written, infor-
med consent prior to the start of the study.
Participants
Healthy male and female volunteers, aged between ≥18
and ≤55 years with body mass index (BMI) ≥18.5 kg/m2
and ≤29.9 kg/m2, who were judged to be in good health
based on medical history, physical examination, ECG and
routine laboratory evaluations were eligible to enter the
trial. Participants were excluded if there was evidence of a
clinically relevant disease, history of risk factors for QT
prolongation (e.g. heart failure, hypokalaemia, family
history of Long QT Syndrome), any clinically relevant
deviations in blood pressure, pulse or ECG, or a marked
baseline prolongation of QT/QTc interval (e.g. repeated
occurrence of >450 ms interval). No concomitant therapy
was allowed except for oral contraceptives. Volunteers
were recruited at a single centre: Human Pharmacology
Centre, Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach, Germany.
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ECG recordings were made at screening and at the end
of the study as part of the safety evaluation. For the QTc
evaluation, ECG recordings were made on study drug
administration days (as ECG profiles) at 60, 50 and
40 minutes pre-dose (to derive the period-specific base-
line), and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours
post-dose (last three time points omitted for moxifloxacin
treatment). At each time point, triplicate standard 12-lead
ECGs (I, II, III, aVR, aVL, aVF, V1–V6) of 10 seconds’
duration each were recorded after at least 5 minutes’ rest
in the supine position using CardioSoft ECG recording
machines (GE Healthcare, Freiburg, Germany). ECGs
were sent to a central laboratory for evaluation of PR,
QRS, RR and QT intervals. The semi-automatic approach
used for determination of the fiducial points provided an
automatic pre-assessment using a computer algorithm,
which was reviewed by a specialist and adjusted if neces-
sary. This review was performed blinded with regard to
treatment and time point.
Data from four cardiac cycles per ECG were averaged.
A population heart rate-corrected QT interval (QTcN)
was derived by determining the exponent δ of the rela-
tionship: QT~ (1000 / RR)δ (where δ is the regression
effect of the covariate) using a linear mixed model on
log-transformed RR and QT data (measured in ms). Data
from triplicate ECGs were then averaged for each time
point. Correction for heart rate is necessary to allow QT
interval comparisons to be independent of potential
changes in heart rate (e.g. due to natural variability or
circadian rhythm), and this method has been shown to be
superior than others commonly used for this purpose [29].
Blood samples for pharmacokinetic measurements
were taken one hour before drug administration and at
the same post-dose time points as ECG measurements,
except for the moxifloxacin periods. Empagliflozin
concentrations in plasma were determined using a
validated high performance liquid chromatography,
tandem mass spectrometry (HPLC-MS/MS) assay with a
lower limit of quantification of 1.11 nmol/L (0.5 ng/mL).
Results were calculated using peak area ratios and
calibration curves were created using weighted (1/x2)
quadratic regression. This method demonstrated accep-
table precision and accuracy of quality control samples, and
the stability of empagliflozin and [13C6]-empagliflozin was
verified under a variety of conditions. Pharmacokinetic
parameters included Cmax, tmax which were deter-
mined directly from the plasma concentration-time
profiles of each, and area under the plasma concen-
tration curve from zero to the last quantifiable time
point (AUC0–tz), calculated using the linear tra-
pezoidal method for ascending concentrations and the
log trapezoidal method for descending concentrations.
Pharmacokinetic parameters were determined usingWinNonlin™ software v5.2 (Pharsight Corporation,
Mountain View, California, USA).
Endpoints
The primary endpoint was the mean change from baseline
(MCfB) in QTcN which was the mean QTcN derived from
ECGs obtained 1–4 hours post-dose minus mean QTcN
from baseline ECGs obtained pre-dose at each visit. Plasma
concentrations of both empagliflozin and moxifloxacin
were expected to reach peak levels within this three-hour
window [10,25], ensuring the most relevant levels of drug
exposure. Use of pre-dose period baseline ECGs has been
shown to be the least variable method of baseline correc-
tion [30], and three triplicate ECG recordings were used in
order to reduce the baseline variance further [31].
Secondary endpoints were the changes from period
baseline in QTcN at any time point between 0.5–
24 hours after dosing. In addition, the MCfB 2–4 hours
after dosing (for assessment of the moxifloxacin effect)
[32], and the MCfB of all ECGs taken 0.5–24 hours after
dosing were evaluated. Safety and tolerability were evalu-
ated based on physical examination, vital signs, ECG,
clinical laboratory tests, adverse events (AEs) and the
physician’s assessment of global tolerability.
Sample size
Detailed considerations relating to the sample size calcula-
tion have been published previously [22]. In summary, the
required sample size for this trial with two placebo periods
was calculated to be 30 volunteers, with 90% overall power
maintained if up to three volunteers discontinued the trial
prematurely. The calculation was based on considerations
for a corresponding TQT trial with only one placebo
period, which would achieve the same power with 36
completing subjects, using the following assumptions:
1) An expected difference of approximately 2 ms in the
primary endpoint between empagliflozin and placebo, and
its common standard deviation of 14 ms.
2) The power of about 95% for testing the primary
endpoint in each dose of empagliflozin against placebo
to achieve an overall power of 90% for the trial, as the
null hypotheses of both primary tests were to be rejected
simultaneously.
The resulting sample size was also sufficient to detect
a treatment difference between moxifloxacin and pla-
cebo of 8 ms in the mean QTcN change from baseline,
with a power of about 95%. Moreover, the sample size
has also been demonstrated to provide sufficient power
to investigate the secondary endpoints (changes in
QTcN interval over time) in previous trials [33–35].
Randomisation
A specific Williams design was selected (see Figure 5 in
[22]), which ensured that no volunteer would receive
Table 2 Demographics and baseline characteristics
(treated set)
Randomised volunteers, n 30
Male gender, n (%) 16 (53.3)
Number completing study, n (%) 27 (90.0)
Baseline characteristics Median (range)
Age (years) 32.5 (18−52)
Height (cm) 170.5 (161−184)
Weight (kg) 68.0 (52−88)
BMI (kg/m2) 23.2 (19.1−28.4)
Heart rate (bpm) 56.0 (42.0−75.0)
QT interval (ms) 403.5 (363.0−475.0)
QTcN interval (ms) 399.0 (372.5−440.3)
BMI, body mass index; bpm, beats per minute; QTcN, population heart rate-
corrected QT interval.
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two of the five periods. The assignment of the four study
treatments to the five symbols (A–E) and the generation
of the randomisation schedule were performed at an in-
dependent site to ensure treatment administration was
double-blind (except for moxifloxacin, which was ad-
ministered open-label). Volunteers were assigned to
three cohorts with 10 volunteers each in agreement with
the randomisation blocking factor of 10.
The randomisation list was generated using a validated
software system (Clinical Trial Supply System Propack
Data CTM, Version 3.3), and the resulting allocation of
treatment sequences to study subjects was both repro-
ducible and non-predictable. Access to the randomisa-
tion code was restricted until the trial was completed
and the database was locked.
Statistical analyses
Adaptations of the conventional analysis in TQT studies
were implemented to account for the inclusion of two
placebo periods. Statistical analyses were planned as de-
scribed previously [22].
Briefly, the primary analysis compared changes in the
primary endpoint (QTcN MCfB over 1–4 hours) using
an analysis of covariance (ANCOVA) model with ‘se-
quence’, ‘period’ and ‘treatment’ as fixed effects, ‘subjects
nested within sequences’ as a random effect, and ‘pre-
dose baseline’ as a covariate. Analyses were performed
using pair-wise comparisons of the trial treatments
[36,37]. The saturated repeated measurements crossover
(RMC) model with unstructured covariance using pair-
wise comparisons of the trial treatments was used to
evaluate changes from baseline in QTcN at any time
point between 0.5–24 hours after dosing [36]. In this
trial, the placebo corrected MCfB was determined using
the data from both placebo periods and the test treat-
ment simultaneously in the ANCOVA model. For de-
scriptive statistics and the exposure-response analysis,
the changes from baseline in QTcN of the placebo pe-
riods were averaged prior to the derivation of the pla-
cebo corrected MCfB.
In agreement with ICH E14, all tests were performed
one-sided against the threshold level of regulatory con-
cern of 10 ms with type-I error of α=5%, which is statis-
tically equivalent to the calculation of two-sided 90%
confidence intervals for the adjusted mean estimates. As
the null hypothesis was tested simultaneously for both
dosage regimens, no alpha adjustment was required tak-
ing into account the partition principle. In addition, an
exposure-response analysis between empagliflozin con-
centrations and placebo-corrected QTcN change from
baseline was carried out [38].
Sensitivity analyses included the adjustment for global
average baseline [39], and direct analysis of the QTinterval with RR interval as additional covariate within the
ANCOVA analysis (one-step procedure [34,36,39,40]).
Subgroup analyses included an analysis of the primary and
secondary endpoints with respect to gender [41]. Assay
sensitivity was tested using the placebo-corrected MCfB in
QTcN 2–4 hours post-dose (global test [32]) for moxi-
floxacin 400 mg using a one-sided superiority test. No
multiplicity adjustments were necessary for the primary
and secondary analyses (intersection–union test [42]).
Categorical endpoints such as AEs, cardiologic assess-
ments and occurrence of ECG intervals beyond thresh-
olds of regulatory concern (e.g. QTc >450 ms) were
analysed based on incidence rates adjusted for the num-
ber of periods in which the treatment was given. Add-
itionally, the analysis of such events in periods with any
of the two doses of empagliflozin compared with the
two placebo periods provides a direct comparison of in-
cidence rates [22]. All analyses were performed on the
“full analysis set”, which comprised all recorded data of
all subjects who received at least one dose of study treat-
ment and had at least one ECG endpoint assessment at
baseline and post treatment. No imputation for missing
data was planned or performed.Results
Patient characteristics
Thirty Caucasian volunteers (16 male [53.3%] and 14
female [46.7%]) were included in the study; demogra-
phics and baseline characteristics are presented in
Table 2. Twenty-seven volunteers completed the study;
one female volunteer died in a car accident four days
after administration of moxifloxacin in treatment period
four, while two male volunteers withdrew consent during
the study (Figure 1).
Figure 1 Patient flow (five-period crossover design).
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The placebo-corrected MCfB in QTcN 1–4 hours after
dosing were 0.6 (90% confidence interval [CI]: -0.7, 1.9)
ms for 25 mg empagliflozin and -0.2 (-1.4, 0.9) ms for
200 mg empagliflozin (Table 3). Hence, the upper limit
of both 90% CIs was below the pre-defined (ICH E14)
threshold of 10 ms, indicating no clinically relevant
prolongation in the mean QTcN interval 1–4 hours after
administration of either 25 mg or 200 mg empagliflozin,
compared with placebo.Secondary endpoints
The placebo-corrected MCfB in QTcN from all ECGs
taken between 0.5–24 hours after dosing was 0.7 (90%
CI: -0.4, 1.7) ms for 25 mg empagliflozin and -0.2 (-1.2,
0.9) ms for 200 mg empagliflozin. The time courses ofTable 3 Adjusted mean (90% CI) values for QTcN and heart ra




















Adjusted means and upper and lower 90% confidence intervals (CI) for the mean p
for the mean heart rate (HR) changes from baseline between 1 and 4 hours after ad
between 2–4 hours after administration of 400 mg moxifloxacin or placebo. Data frthe adjusted means of the placebo-corrected QTcN
changes from baseline for each active treatment are
presented in Figure 2A. Compared with placebo, the ad-
justed mean values ranged from -2.7 to 2.2 ms after dos-
ing with 25 mg empagliflozin and -1.8 to 1.6 ms with
200 mg empagliflozin. Maximum upper CIs were 4.7
and 3.5 ms, respectively, clearly below the pre-defined
threshold of 10 ms.
Assay sensitivity was confirmed by placebo-corrected
MCfB in QTcN 2–4 hours post-dose of 12.4 (10.7, 14.1)
ms with moxifloxacin 400 mg (Figure 2A, Table 3).Sensitivity analyses
Based on regulatory requirements, a number of sen-
sitivity analyses were carried out. Additional analyses
included an ANCOVA model with a global baseline,te mean changes from baseline
om placebo:
N (ms)












(-0.7, 1.9) -0.3 (0.4) -0.9 (0.5) (-1.8, 0.0)
-1.2 (0.5)
(-1.4, 0.9) -0.3 (0.4) 0.0 (0.5) (-0.9, 0.8)
-0.3 (0.5)
(10.7, 14.1) -0.2 (0.4) 2.2 (0.6) (1.1, 3.3)
2.0 (0.6)
opulation heart rate-corrected QT interval (QTcN) changes from baseline and
ministration of 25 mg or 200 mg doses of empagliflozin or placebo and
om the full analysis set. SE, standard error; bpm, beats per minute.
Figure 2 Placebo-corrected QTcN CfB (A) and placebo-corrected heart rate CfB (B). Data are adjusted means and 90% confidence intervals
(CIs) after administration of empagliflozin 25 mg, or 200 mg, or moxifloxacin 400 mg. Data from the full analysis set analysed: placebo (n=29);
25 mg empagliflozin group (n=28); 200 mg empagliflozin group (n=30); and 400 mg moxifloxacin group (n=29). CfB, change from baseline;
HR, heart rate; QTcN, population heart rate-corrected QT interval.
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stage-analysis of QT prolongation [40] or the Patterson
model [43]. Results of these analyses were in agreement
with the primary and secondary analysis of the trial.
Other ECG parameters
Additional analyses were performed for heart rate and
other heart rate-corrected QTc endpoints (QTcI, indivi-
dual heart rate-corrected QT interval; QTcF, Fridericia’s
correction formula; QTcB, Bazett’s correction formula).
The estimated parabolic slope for the study population
correction method (QTcN) was 0.294, and thus slightly
lower than the slope used with the Fridericia method
(0.333). The estimated slopes for the individual correc-
tion method ranged from 0.174 to 0.421.For both empagliflozin doses, the time courses for the
adjusted means of the placebo-corrected heart rate
change from baseline ranged from -1.2 to 1.5 bpm, and
all 90% CIs were between -3 to 3 bpm (Figure 2B). As
the changes in heart rate were small (Table 3), the
results of the uncorrected QT interval and other heart
rate-corrected QT intervals were very similar to those of
the primary and secondary analyses.
In the categorical analysis on QTc endpoints, five
volunteers exceeded the QTcN threshold of 450 ms
during the treatment period (0.5–24 hours post-dose for
empagliflozin, and 0.5–6 hours post-dose for moxifloxacin);
with one (3.6%) volunteer taking 25 mg empagliflozin, two
(6.7%) volunteers taking 200 mg empagliflozin and two
(6.9%) volunteers taking moxifloxacin. QTcN did not
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data from both placebo periods), and QTcN did not
exceed 480 ms in any volunteer. Five volunteers had a
change in QTcN more than 30 ms, all of whom were
taking moxifloxacin.
Individual ECG data were analysed for notable changes
from the pre-dose assessments in heart rate, PR, and
QRS intervals. These were defined as heart rate percen-
tage change ≥25% and observed heart rate value <50 bpm
or >100 bpm; PR percentage increase ≥25% and observed
PR value >200 ms; QRS percentage increase ≥10% and
observed QRS value >110 ms. No individual presented a
notable change in any of these categories, and there were
no clinically relevant findings in placebo-adjusted changes
from baseline.
Gender effects
Analysis of the primary and secondary endpoints by gender
also demonstrated the absence of a clinically relevant
placebo-corrected change from baseline in QTcN after
administration of 25 mg and 200 mg doses of empagliflozin.
Despite the low sample sizes in each gender subgroup, all
90% CIs of the primary and secondary endpoints were
between -7 and 7 ms in each of the subgroups, and no clin-
ically relevant differences between male and female
volunteers were noted.
Pharmacokinetic parameters
Following oral administration, empagliflozin was rapidly
absorbed, reaching median peak levels at approximately
1.5 and 1.8 hours with the 25 mg and 200 mg doses,
respectively (Table 4). Thus, for both doses, Cmax was
reached within the pre-defined three-hour time window
for ECG measurements for the primary endpoint.
Empagliflozin exposure increased approximately dose
proportionally with the two tested doses (Table 4).
Pharmacokinetic-pharmacodynamic evaluation
The exposure-response analysis for placebo-corrected
QTcN change from baseline for both empagliflozin doses
resulted in slope estimates that were zero or close to
zero and their two-sided 95% CIs included zero (Table 5;Table 4 Pharmacokinetic parameters for single empagliflozin






AUC0–tz, area under the concentration-time curve of empagliflozin in plasma over th
in plasma; Cmax, maximum plasma concentration of empagliflozin; and tmax, time to
set analysed per protocol: 25 mg empagliflozin dose group (n=28), 200 mg empagl
of variance.Figure 3A). Similar results were obtained for the rela-
tionship between empagliflozin and heart rate, with
slope estimates close to zero and CIs that include zero
for both doses (Figure 3B). These results demonstrate no
relationship between empagliflozin exposure and either
prolongation of the QTcN interval or change in heart
rate compared with placebo.
Safety and tolerability
Overall, 15 of 30 volunteers (50%) experienced AEs during
the trial; three of 28 volunteers (10.7%) taking 25 mg
empagliflozin, five of 30 (16.7%) taking 200 mg empa-
gliflozin, eight of 29 (27.6%) taking placebo, and one of 29
(3.4%) taking moxifloxacin. None were considered by the
investigator to be related to the study medication.
The one serious AE leading to study discontinuation
was the fatal car accident in one participant receiving
moxifloxacin. In addition, two other volunteers developed
severe AEs (nasopharyngitis of severe intensity on placebo
and headache of severe intensity on 25 mg empagliflozin).
The most frequent AE was nasopharyngitis, reported
by nine volunteers: five (17.2%) taking placebo, two
(7.1%) taking 25 mg empagliflozin, and two (6.7%) taking
200 mg empagliflozin. Other AEs included headache in
one volunteer taking 25 mg empagliflozin (3.6%) and
two taking placebo (6.9%) and oropharyngeal pain in
one volunteer taking 200 mg empagliflozin (3.3%) and
one taking placebo (3.4%). Nausea, vomiting and skin
rash AEs were each reported in one volunteer (3.3%)
taking 200 mg empagliflozin. The remaining AEs (arth-
ropod bite and car accident) were each experienced by
one volunteer (3.4%) taking placebo and moxifloxacin,
respectively.
Efficiency of the new trial design
Another sensitivity analysis compared the effect of the
pooled, double placebo design with the use of single
placebo periods in the primary and secondary analyses.
The results for the primary analysis are shown in Table 6.
As expected [22], the standard error of the placebo-
corrected change from baseline of QTcN was inflated by
about 15%, on average, when only one of the placebodoses of 25 mg and 200 mg
Empagliflozin 200 mg





e time interval 0–time of the last measurable concentration of empagliflozin
maximum plasma concentration of empagliflozin. Data from the full analysis
iflozin dose group (n=30). gMean, geometric mean; gCV, geometric coefficient
Table 5 Slope and intercept from the exposure-response analysis of placebo-corrected QTcN change from baseline by dose
Slope [ms/(nmol/L)] Predicted value of placebo-corrected change
from baseline QTcN (ms) at gMean of Cmax
Treatment Intercept (ms) Estimate 95% CI gMean of Cmax (nmol/L) Estimate 90% CI
Empagliflozin 25 mg 0.35 -0.0007 -0.0043, 0.0029 768 -0.20 -1.65, 1.24
Empagliflozin 200 mg -0.60 -0.0000 -0.0005, 0.0005 4860 -0.64 -2.33, 1.05
Predicted values and confidence intervals (CI) determined by the exposure-response relationship of empagliflozin (25 mg or 200 mg treatment group). Data from
the full analysis set. QTcN, population heart rate-corrected QT interval.
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This demonstrated that the assumptions for using this
design [22] were fulfilled; i.e. that the changes from
baseline showed low intra-individual correlation between
the two placebo periods.Figure 3 Empagliflozin exposure-response relationships for placebo-c
Placebo-corrected changes from baseline versus plasma concentrations of
treatment groups. HR, heart rate; QTcN, population heart rate-corrected QTDiscussion
The prolongation of cardiac repolarisation, as measured
by the QT interval, can potentially increase the probabil-
ity of fatal cardiac arrhythmia [44]. As such, TQT studies
of new drugs are recommended by regulatory guidelinesorrected QTcN (A) and heart rate (B) changes from baseline.
empagliflozin for empagliflozin 25 mg and empagliflozin 200 mg
interval. Data from the full analysis set.
Table 6 Additional sensitivity analysis comparing use of 1 or 2 placebo periods for the primary analysis
Placebo-corrected adjusted means and 90% CIs for the mean QTcN change from baseline 1−4 hours after dosing analysed using
two different ANCOVA models
ANCOVA model 25 mg empagliflozin Difference
from placebo, ms
200 mg empagliflozin Difference
from placebo, ms
Mean (SE) 90% CI Mean (SE) 90% CI
Primary analysis model with placebo period 1 only 0.2 (0.9) (-1.4, 1.8) -0.5 (0.8) (-1.8, 0.8)
Primary analysis model with placebo period 2 only 0.6 (1.0) (-1.2, 2.4) 0.1 (0.8) (-1.4, 1.5)
Data from full analysis set (n=30). ANCOVA, analysis of covariance; CI, confidence interval; QTcN, population heart rate-corrected QT interval.
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cardiac repolarisation [12,24]. TQT studies determine
whether the drug has a threshold pharmacologic effect
on cardiac repolarisation, as detected by QT/QTc pro-
longation [12,24]. A negative TQT study is indicated
when the upper bound of the 95% one-sided CI for the
largest time-matched mean effect of the drug on the
QTc interval excludes 10 ms. TQT studies are typically
carried out in healthy subjects at early stages of drug
development [12,24]. Further investigation in the target
patient population is generally only required following a
positive TQT study; following a negative TQT study, the
collection of baseline and periodic on-therapy ECGs
during subsequent stages of drug development is gene-
rally sufficient [12,24]. There are some data to suggest
that there may be inter-ethnic differences in drug-
induced QT-prolongation effects [45], and that risk of
QT interval prolongation may be increased in females,
patients with organic heart diseases and patients with
hypokalaemia [46], but further investigation of these
factors is required.
This randomised, double-blind, placebo-controlled
trial (with open-label moxifloxacin), employing a new
five-period crossover design with two placebo periods,
aimed to assess the effects of empagliflozin on QT inter-
val in healthy volunteers, according to the ICH E14
guideline [12,24]. Empagliflozin was found to have no
effect on population heart rate-corrected QTc interval
length measured in healthy volunteers at either thera-
peutic (25 mg) or supratherapeutic (200 mg) doses. The
placebo-corrected QTcN interval changes from baseline
after administration of 25 mg or 200 mg empagliflozin
were below the threshold of regulatory concern of
10 ms, both in the pre-defined interval, as well as over
the whole time course. In addition, there were no clinic-
ally relevant findings regarding the placebo-corrected
changes from baseline for heart rate or any of the other
heart rate-corrected QTc intervals that were investi-
gated. Subgroup analyses by gender also demonstrated
the absence of a significant effect of treatment on the
primary endpoint (mean change from baseline in the
QTcN between 1–4 hours after dosing). Furthermore,
exposure-response analysis confirmed the lack of a rela-
tionship between empagliflozin exposure and QTinterval length. No other clinically relevant changes in
ECG parameters were observed after empagliflozin
administration. Also assay sensitivity was shown with
QTc effects of moxifloxacin, which were consistent with
previous reports [25].
The five-period crossover design employed in this
TQT study has been shown to be more efficient than
the usual four-period design for TQT trials. The
design is based on the objective that all comparisons
are performed between active drugs and placebo, and
no comparisons between active drug groups are
necessary [22]. Furthermore, the use of two placebo
periods increases the number of measurements taken
while on placebo, thus reducing the variability of
placebo estimates and of placebo-corrected values for
active treatment groups. As a consequence, a 25%
smaller sample size is required to achieve the same
power as the corresponding four-period trial design
[22,23,47].
The sample size required to maintain an overall power
of 90% for this five-period TQT trial was 30 subjects
(including three potential drop-outs), compared with 40
subjects (including four potential drop-outs) in a conven-
tional four-period design [22]. Moreover, the number of
ECG recording sessions was reduced by 7% (150 com-
pared with 160), leading to a reduction in cost and effort
of a similar magnitude.
The results obtained from ECG recordings in this
study are consistent with a lack of relevant ECG-related
effects observed during the pre-clinical and clinical
development of empagliflozin to date. In vitro and ani-
mal studies with empagliflozin demonstrated no relevant
interactions with the hERG-mediated potassium current
and no effect on action potentials (unpublished data).
There were also no clinically relevant changes to ECG
recordings made in clinical trials of both healthy volun-
teers [10] and patients with T2DM [48]. These clinical
studies also noted an absence of any relevant placebo-
corrected changes from baseline in heart rate after
empagliflozin administration. The cardiovascular safety
of empagliflozin in patients with T2DM continues to be
studied as part of the Phase III study program and is
being investigated in a dedicated cardiovascular outcome
trial (NCT01131676).
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empagliflozin in the current study are consistent with
the findings of previous studies in healthy volunteers
[10] and patients with T2DM [48,49]. The safety findings
of this study were also in line with previous clinical stu-
dies conducted in both healthy volunteers and patients
with T2DM [8,10,48]. Single doses of empagliflozin were
well tolerated. The majority of AEs were mild to mode-
rate in severity (the most frequent being nasopha-
ryngitis) and none were considered to be related to
study medication.
Conclusions
In conclusion, this study, conducted according to ICH
E14 guidance, has shown that empagliflozin was not
associated with QTc interval prolongation at therapeutic
and supratherapeutic doses, and was well tolerated by
male and female healthy volunteers. The new double-
placebo period study design proved to be efficient for
TQT trials.
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